27 January 2016 - Getting U.S. government and commercial insurers to cover new medicines can now take longer than in Europe, Swiss drugmaker Novartis said on Wednesday, blaming U.S. delays for weaker than expected sales of a key heart failure treatment.

For more details, go to: http://www.reuters.com/article/us-novartis-results-insurers-idUSKCN0V527F